Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more ...
A large study from the University of East Anglia has found a possible link between certain medications and a higher risk of ...
Phase 2 ASCEND trial of solengepras, a novel, non-dopaminergic GPR6 inhibitor, showed evidence of potential benefit in functional and non-motor ...
Recently FDA-cleared, adaptive deep brain stimulation is gaining global traction, offering real-time, personalized therapy ...
A large international team of researchers has found that deep brain stimulation in the subthalamic nucleus continues to help ...
1mon
Early intervention can make ‘huge impact’ on Parkinson’s patients despite long Manitoba wait times
Experts tasked with helping Manitobans living with Parkinson's disease say long wait times are making patients' journeys more ...
New research shows adaptive deep brain stimulation is safe and effective in Parkinson care. Keep reading to see future ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback